Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Andorra Health Watch.
Press releases published on July 29, 2025
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
TILsRx platform designed to overcome immune suppression and T cell exhaustion to activate tumor-infiltrating lymphocytes (TILs) Multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets A preferred …
Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to 60mCi of Lu177 On track to complete enrollment of the first cohort of Phase 1 ‘HEAT’ trial of RAD202 for treatment of advanced …
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $625 - $640 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis …
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on …
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Revenue of $182 million, year-over-year increase of 15% as reported and 17% organic non-COVID growth Orders grew sequentially and greater than 20% year-over-year Increasing revenue guidance to range of $715 to $735 million, which represents 12.5% -15.5% …
Quipt Home Medical Corp. to Announce Fiscal Third Quarter 2025 Financial Results on August 11, 2025
CINCINNATI, July 29, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal Third quarter 2025 financial …
QuasarMD Unveils Advanced Full-Body Light Therapy Mat to Support Aging Wellness
CHINO, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- QuasarMD LLC, a leader in light-based wellness technologies, announces the launch of its Full-Body Light Therapy Mat, a clinically validated, non-invasive solution designed to address the evolving wellness …
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 2025 ~ ~ Presented …
Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025
PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results on Monday, August 4, 2025, prior to …
Microbix Launches QUANTDx™ Characterized Reference Materials
MISSISSAUGA, Ontario, July 29, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QUANTDx™, a new product line of well- …
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company …
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – – Over 800 patients enrolled across the LUGANO and …
Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease
MENLO PARK, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve …
Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for Treating Patients with Cerebral Ischemic Stroke
The Phase 3 clinical trial of sovateltide, RESPECT-ETB, is expected to enroll over 500 patients with a primary endpoint of proportion of patients demonstrating functional independence at 90 days and is being conducted under a Special Protocol Assessment ( …
Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025
NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, …
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, …
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
Boca Raton, July 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be published on the …
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events (SAEs) ― ― Observed robust and rapid pan- …
Glucose Health, Inc. (OTC: GLUC) Highlights U.S. Department of Health and Human Services Designation of Key Nutrient Validating Company’s Patent-Pending Nutrition Formulation via CNBC, Fox Business and Bloomberg Television Media Blitz
BENTONVILLE, Ark., July 29, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a publicly traded consumer healthcare company focused on diabetic nutrition and soluble fiber-based nutrition formulations, today announced the launch of a targeted …
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an …